PortViewPortView
Cerenome logo

Cerenome (CNSY) Stock Analysis

NASDAQHealthcareMedical - Pharmaceuticals

$2.89+6.48%
1-year price historyRange $2.71 – $4.28
52-week range$2.89
$2.62$23.50

What Cerenome does

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

Key metrics

Market cap
$19.86M
P/E (TTM)
-0.40
EPS (TTM)
$-7.19
Beta
1.43
Dividend yield
0.00%
Revenue / share
$0.62
50-day avg
$3.70
200-day avg
$7.20
52-week high
$23.50
52-week low
$2.62
CEO
Marc H. Hedrick

ETFs linked to CNSY

Broad-market and Healthcare sector ETFs an investor holding Cerenome is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CNSY fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze CNSY in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Cerenome?
Cerenome trades under the ticker CNSY on NASDAQ.
Which exchange is CNSY listed on?
CNSY is listed on NASDAQ.
What sector does Cerenome operate in?
Cerenome is classified in the Healthcare sector (Medical - Pharmaceuticals industry).
How can PortView help analyze CNSY in a portfolio?
PortView shows CNSY's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.